Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes

被引：0
|
作者：
Zeqing Zhang
Xi Chen
Puhan Lu
Jianhua Zhang
Yongping Xu
Wentao He
Mengni Li
Shujun Zhang
Jing Jia
Shiying Shao
Junhui Xie
Yan Yang
Xuefeng Yu
机构：
[1] Huazhong University of Science and Technology,Division of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College
来源：
Cardiovascular Diabetology | / 16卷
关键词：
Glucagon-like peptide-1 agonists; Dipeptidyl peptidase-4 inhibitors; Type 2 diabetes mellitus; Cardiovascular outcomes; Acute pancreatitis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] SGLT2 Inhibitors or GLP-1 Receptor Agonists Reduce Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Shaughnessy, Allen F.
    AMERICAN FAMILY PHYSICIAN, 2021, 104 (02) : 206 - 206
  • [32] INSULIN IS MOST APPROPRIATE COMPARATOR TO GLP-1 RECEPTOR AGONISTS AND DPP-4 INHIBITORS IN REAL-WORLD CARDIOVASCULAR OUTCOME STUDIES
    Ali, A. K.
    Motsko, S. P.
    VALUE IN HEALTH, 2017, 20 (05) : A311 - A311
  • [33] Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors)
    Charalampos I. Liakos
    Dimitrios P. Papadopoulos
    Elias A. Sanidas
    Maria I. Markou
    Erifili E. Hatziagelaki
    Charalampos A. Grassos
    Maria L. Velliou
    John D. Barbetseas
    American Journal of Cardiovascular Drugs, 2021, 21 : 123 - 137
  • [34] Effects of DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors and sulphonylureas on mortality, cardiovascular and renal outcomes in type 2 diabetes: A network meta-analyses-driven approach
    Bronden, Andreas
    Christensen, Mikkel Bring
    Glintborg, Dorte
    Snorgaard, Ole
    Kofoed-Enevoldsen, Allan
    Madsen, Gitte Krogh
    Toft, Katja
    Kristensen, Jette Kolding
    Hojlund, Kurt
    Hansen, Troels Krarup
    Sondergaard, Esben
    Hansen, Katrine Bagge
    DIABETIC MEDICINE, 2023, 40 (08)
  • [35] Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors)
    Liakos, Charalampos I.
    Papadopoulos, Dimitrios P.
    Sanidas, Elias A.
    Markou, Maria I.
    Hatziagelaki, Erifili E.
    Grassos, Charalampos A.
    Velliou, Maria L.
    Barbetseas, John D.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2021, 21 (02) : 123 - 137
  • [36] SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
    El Mouhayyar, Christopher
    Riachy, Ruba
    Khalil, Abir Bou
    Eid, Asaad
    Azar, Sami
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2020, 2020
  • [37] DPP-4 inhibitors vs GLP-1 receptor agonists after failure of metformin monotherapy in type 2 diabetes
    Hernandez Mijares, A.
    AVANCES EN DIABETOLOGIA, 2010, 26 (03): : 200 - 202
  • [38] DPP-4 inhibitors vs GLP-1 receptor agonists after failure of metformin monotherapy in type 2 diabetes
    Hernandez Mijares, A.
    AVANCES EN DIABETOLOGIA, 2010, 26 (04): : 270 - 272
  • [39] DPP-4 Inhibitors and GLP-1 Receptor Agonists for Prevention or Delay of Type 2 Diabetes Mellitus and Associated Complications
    Smith, Dustin K.
    Wessner, Matthew J.
    AMERICAN FAMILY PHYSICIAN, 2018, 97 (07) : 437 - 438
  • [40] Impact of GLP-1 and GLP-1 Receptor Agonists on Cardiovascular Risk Factors in Type 2 Diabetes
    Verge, Danilo
    Lopez, Ximena
    CURRENT DIABETES REVIEWS, 2010, 6 (04) : 191 - 200
12345